Business Description
Finch Therapeutics Group Inc
NAICS : 325412
SIC : 2834
ISIN : US31773D2009
Description
Finch Therapeutics Group Inc is a microbiome technology company with a portfolio of intellectual property and microbiome assets. Finch has a robust intellectual property estate reflecting the company's pioneering role in the microbiome therapeutics field, including more than 70 issued U.S. and foreign patents with critical relevance for both donor-derived and donor-independent microbiome therapeutics in a range of potential indications. The company's assets include CP101, an investigational, orally administered microbiome candidate with positive clinical date from a Phase 2 randomized, placebo-controlled trial and a Phase 2 open-label trial in recurrent C. difficile infection (CDI).
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.83 | |||||
| Equity-to-Asset | 0.41 | |||||
| Debt-to-Equity | 1.32 | |||||
| Debt-to-EBITDA | -0.88 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -13.07 | |||||
| Beneish M-Score | -5.35 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -76.3 | |||||
| 3-Year EBITDA Growth Rate | 7.1 | |||||
| 3-Year EPS without NRI Growth Rate | 13 | |||||
| 3-Year FCF Growth Rate | 4 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 42.73 | |||||
| 9-Day RSI | 45.32 | |||||
| 14-Day RSI | 46.13 | |||||
| 6-1 Month Momentum % | -31.39 | |||||
| 12-1 Month Momentum % | -79.61 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.33 | |||||
| Quick Ratio | 6.33 | |||||
| Cash Ratio | 6.15 | |||||
| Days Sales Outstanding | 428.11 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.6 | |||||
| Shareholder Yield % | 254.49 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -33265.42 | |||||
| Net Margin % | -71351.4 | |||||
| FCF Margin % | -29457.01 | |||||
| ROE % | -185.98 | |||||
| ROA % | -90.09 | |||||
| ROIC % | -74.11 | |||||
| ROC (Joel Greenblatt) % | -108.38 | |||||
| ROCE % | -47.17 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 33.39 | |||||
| PB Ratio | 0.16 | |||||
| Price-to-Tangible-Book | 0.16 | |||||
| EV-to-EBIT | -0.24 | |||||
| EV-to-Forward-EBIT | -0.13 | |||||
| EV-to-EBITDA | -0.26 | |||||
| EV-to-Forward-EBITDA | -0.16 | |||||
| EV-to-Revenue | 81.26 | |||||
| EV-to-Forward-Revenue | 73.6 | |||||
| EV-to-FCF | -0.28 | |||||
| Earnings Yield (Greenblatt) % | -416.67 | |||||
| FCF Yield % | -876.01 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:FNCH
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Finch Therapeutics Group Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.107 | ||
| EPS (TTM) ($) | -47.63 | ||
| Beta | 0.46 | ||
| Volatility % | 42.99 | ||
| 14-Day RSI | 46.13 | ||
| 14-Day ATR ($) | 0.402243 | ||
| 20-Day SMA ($) | 2.404495 | ||
| 12-1 Month Momentum % | -79.61 | ||
| 52-Week Range ($) | 1.86 - 16.74 | ||
| Shares Outstanding (Mil) | 1.61 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Finch Therapeutics Group Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Finch Therapeutics Group Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Finch Therapeutics Group Inc Frequently Asked Questions
What is Finch Therapeutics Group Inc(FNCH)'s stock price today?
The current price of FNCH is $2.24. The 52 week high of FNCH is $16.74 and 52 week low is $1.86.
When is next earnings date of Finch Therapeutics Group Inc(FNCH)?
The next earnings date of Finch Therapeutics Group Inc(FNCH) is 2024-05-10 Est..
Does Finch Therapeutics Group Inc(FNCH) pay dividends? If so, how much?
Finch Therapeutics Group Inc(FNCH) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers